CompanyGraph
Simcere Pharmaceutical Group Ltd.
2096 · HKEX · China
Price data from its S2P listing on XSTU, quoted in EUR
simcere.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $4.51B, above the global median of $1.18B
- FinancialsAltman Z-Score 4.64: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.70%Below 5Y avg (2.16%)
Annual Rate
HKD 0.21Paid annual
Payout Ratio
29.6%Sustainable
Payback Period
6.1 yr
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
35.41BHKD4.51B · vs all stocks (USD)
Trailing P/E
19.63xRevenue (TTM)
9.00BCNY1.15B · vs all stocks (USD)
Profit Margin
17.38%Beta
0.7330xvs all stocks
52-Week Change
-1.70%vs all stocks
Market Capitalization
35.41BHKD4.51B · vs all stocks (USD)
Enterprise Value
34.59BHKD4.41B · vs all stocks (USD)
Trailing P/E
19.63xForward P/E
14.51xPrice to Sales (TTM)
4.11xPrice to Book (MRQ)
2.93xEnterprise to Revenue
3.85xEnterprise to EBITDA
17.29xProfit Margin
17.38%Operating Margin
16.95%Return on Assets (TTM)
6.73%Return on Equity (TTM)
16.24%Revenue (TTM)
9.00BCNY1.15B · vs all stocks (USD)
Revenue per Share (TTM)
3.12CNYUpdated Aug 19, 2026Quarterly Revenue Growth
17.70%Gross Profit (TTM)
7.34BCNY936.20M · vs all stocks (USD)
EBITDA (TTM)
1.87BCNY238.62M · vs all stocks (USD)
Net Income (TTM)
1.56BCNY199.41M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
179.00%Operating Cash Flow (TTM)
2.34BCNY298.75M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
903.93MCNY115.24M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2069HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
1.70%vs all stocks
5-Year Average Dividend Yield
2.16%vs all stocks
Payout Ratio
29.58%Minority Interest (Equity)
6.72MCNYFY2025 · Dec 31, 2025Revenue
7.73BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.42BCNYFY2025 · Dec 31, 2025Gross Profit
6.31BCNYFY2025 · Dec 31, 2025Operating Income
1.39BCNY206.80M · vs all stocks (USD)
Pre-tax Income
1.51BCNYFY2025 · Dec 31, 2025Income Tax Expense
170.32MCNYFY2025 · Dec 31, 2025Net Income
1.34BCNYFY2025 · Dec 31, 2025EBIT
1.61BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.87BCNYFY2025 · Dec 31, 2025Research & Development
1.56BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
3.51BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
55.75MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
95.80MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.48BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.48BSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
0.00CNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.52BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.17BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.51BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.51BCNYFY2025 · Dec 31, 2025Stock-based Compensation
89.57MCNYFY2025 · Dec 31, 2025Other Non-cash Items
40.05MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-165.69MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
37.70MCNYFY2025 · Dec 31, 2025Capital Expenditures
-348.57MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-512.88MCNYFY2025 · Dec 31, 2025Net Acquisitions
-5.78MCNYFY2025 · Dec 31, 2025Purchase of Investments
-970.47MCNYFY2025 · Dec 31, 2025Sale of Investments
445.57MCNYFY2025 · Dec 31, 2025Other Investing Activity
710.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-878.54MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.05BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.05BCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-74.30MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-390.75MCNYFY2025 · Dec 31, 2025Other Financing Charges
34.34MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
997.11MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.60BSharesUpdated Aug 19, 2026Float Shares
842.75MSharesUpdated Aug 19, 2026% Held by Insiders
67.52%vs all stocks
% Held by Institutions
13.65%vs all stocks
Total Cash (MRQ)
4.16BCNY530.81M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.38CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.38BCNY176.11M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1261xCurrent Ratio (MRQ)
2.21xBook Value per Share (MRQ)
4.22CNYUpdated Aug 19, 2026Total Assets
14.73BCNY2.18B · vs all stocks (USD)
Total Current Assets
7.39BCNYFY2025 · Dec 31, 2025Total Liabilities
5.31BCNYFY2025 · Dec 31, 2025Total Non-current Assets
7.34BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.97BCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.35BCNYFY2025 · Dec 31, 2025Cash
3.51BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
3.51BCNYFY2025 · Dec 31, 2025Other Short-term Investments
65.53MCNYFY2025 · Dec 31, 2025Accounts Receivable
2.49BCNYFY2025 · Dec 31, 2025Inventory
589.50MCNYFY2025 · Dec 31, 2025Accounts Payable
249.03MCNYFY2025 · Dec 31, 2025Short-term Debt
1.11BCNYFY2025 · Dec 31, 2025Long-term Debt
77.11MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
165.00MCNYFY2025 · Dec 31, 2025Common Stock (Book)
4.62BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
9.41BCNY1.40B · vs all stocks (USD)
52-Week Low
9.07HKDUpdated Aug 19, 202652-Week High
15.08HKDUpdated Aug 19, 202652-Week Change
-1.70%vs all stocks
Beta
0.7330xvs all stocks
50-Day MA
11.40HKDUpdated Aug 19, 2026200-Day MA
12.10HKDUpdated Aug 19, 2026Avg 10-Day Volume
5.84MSharesUpdated Aug 19, 2026Avg 30-Day Volume
6.95MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.6300CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.64: safe zoneNotable
Altman Z-Score: 4.64
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $4.51B, above the global median of $1.18BNotable
Market cap (USD): 4,513,823,674.242Global Median: 1,179,398,897.704
Revenue is $1.15B, above the global median of $534.05MNotable
Revenue (USD): 1,147,111,855.456Global Median: 534,052,387.958
Levered free cash flow is $115.24M, above the global median of $19.19MNotable
Levered free cash flow (USD): 115,241,998.855Global Median: 19,189,974.917
Companies that share the same coordination system — how they create, deliver, or capture value.
Enliven Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LivaNova PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Mgi Tech Co Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Celcuity Inc.
Tier 1ProductionApproval-Gated PipelineRule
Humanwell Healthcare Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Chongqing Zhifei Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ajanta Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tango Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Integer Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Havells India Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
ALK-Abello A/S
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
HBL Engineering Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities